Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab cardiovascular surrogate marker study in chronic plaque psoriasis
2013-002266-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoint: Flow mediated dilation at week 12. Started Oct 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2013-002266-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002266-40.